XCancer

Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413

Description:

The study should evaluate the biological distribution of \[99mTc\]Tc-BQ0413 in patients with prostate cancer. The primary objective are: 1. To assess the distribution of \[99mTc\]Tc- BQ0413 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[99mTc\]Tc- BQ0413. 3. To study the safety and tolerability of the drug \[99mTc\]Tc- BQ0413 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[99mTc\]Tc- BQ0413 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer patients.

Sponsor:

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase:

Phase 1

Contacts:

Vladimir I Chernov, MD,Prof (STUDY_DIRECTOR)

Government Study Link:

NCT06101927 - Click here to see study on

ClinicalTrials.gov

BQ0413

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: mercaptoacetyl-triglutamate
Linker: 2-naphthyl-L-alanine and L-tyrosine
Inclusion
  • Clinical and radiological diagnosis of prostate cancer with histological verification.
Exclusion

Exclusion Criteria Not Yet Provided